# US 2026/0209215 A1 · Glycine derivatives with p2x4 receptor-blocking activity as diagnostics and for the treatment of pain, inflammation, cancer, and other p2x4 receptor-related diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0209215 A1
- Document ID: US20260209215A1
- Status: Published application
- Kind: A1
- Application number: 19/140,808
- Filed: 2023-06-20
- Published: 2026-07-23
- Earliest claimed: 2022-12-20
- Applicants: Rheinische-Friedrich-Wilhelms-UniversitäT Bonn
- Inventors: Christa E. MÜLLER; Victor Hernandez OLMOS; Ahmed ELGOKHA; Ali EL-TAYEB; Mahmoud RASHED; Jörg HOCKEMEYER; Enas MALIK; Samer ALSHAIBANI; Anton IVANOV; Federica ROSI; Svenja WERNER; Thanigaimalai PILLAIYAR; Aliaa ABDELRAHMAN; Vigneshwaran NAMASIVAYAM
- Web page: https://patentgrep.com/patent/US20260209215A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4245: Oxadiazoles
- A61K 31/433: Thidiazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 35/00: Antineoplastic agents
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 451/02: containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D 471/04: Ortho-condensed systems
- C07D 471/06: Peri-condensed systems
- C07D 487/06: Peri-condensed systems
- C07D 491/10: Spiro-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 498/06: Peri-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to glycine derivatives with P2X4 receptor-blocking activity for the treatment of pain, inflammation, cancer, and other P2X4 receptor-related diseases.

## Claims

### Claim 1

A compound according to general Formula (A), general Formula (B), general Formula (C) and/or general Formula (D),
wherein, respectively independently,
Z1 means N or C—R1;
Z2 means N or C—R2;
Z3 means N or C—R3;
A1 means —O—, —S—, N, —CH or C-Rx;
A2 means N, —CH or C-Rx;
A3 means N or C-R11;
A4 means N or C-R12;
A5 means N or C-R13;
B and C, respectively independently, mean —O—, —S—, N, —CH or C-Rx;
D means N, N-Rx or C-R10;
R1, R2, R3, R4, R5, R6, R7, Rs, R9, R10, R1, R12 and R13, respectively independently, mean —H, —F, —Cl, —Br, —I, —CN, —NO2, —CHO, ═O, —Rx, —C(═O)Rx, —C(═O)H, —C(═O)OH, —C(═O)ORx, —C(═O)NH2, —C(═O)NHRx, —C(═O)N(Rx)2, —OH, —ORx, —OC(═O)H, —OC(═O)Rx, —OC(═O)—ORx, —OC(═O)NHRx, —OC(═O)N(Rx)2, —SH, -SRx, —SO3H, —S(═O)1-2-Rx, —S(═O)1-2NH2, —S(═O)1-2NHRx, —S(═O)1-2N(Rx)2, —NH2, —NHRx, —N(Rx)2, —N+(Rx)3, —N+(Rx)2 O−, —NH—S(═O)1-2-Rx, —NHC(═O)Rx, —N(S(═O)2—CH3)(C(═O)Rx), —N(S(═O)2—CH3)2, —NHC(═O)ORx, —NHC(═O)NH2, —NHC(═O)NHRx, —NHC(═O)—N(Rx)2, —Si(Rx)3 or —PO(ORx)2;
or R1 and R2 jointly form a ring, the ring atoms of which respectively independently of one another are C, S or O, wherein the ring is aromatic or non-aromatic, unsubstituted or mono- or polysubstituted by substituents selected independently of one another from the group consisting of —F, —Cl, —Br, —I, —CN, —NO2, —CHO, ═O, —CH3 and —OH,
or R1 and R4 jointly form a ring, the ring atoms of which respectively independently of one another are C, S or O, wherein the ring is aromatic or non-aromatic, unsubstituted or mono- or polysubstituted by substituents selected independently of one another from the group consisting of —F, —Cl, —Br, —I, —CN, —NO2, —CHO, ═O, —CH3 and —OH,
wherein in each case Rx, respectively independently, means —C1-8-aliphatic, -C3-12-cycloaliphatic, -aryl, heteroaryl, —C1-8-aliphatic-C3-12-cycloaliphatic, —C1-8-aliphatic-aryl, —C1-8-aliphatic-heteroaryl, -C3-8-cycloaliphatic—C1-8-aliphatic, -C3-8-cycloaliphatic-aryl or -C3-s-cycloaliphatic-heteroaryl;
wherein in each case “aliphatic”, respectively independently, means a branched or unbranched, saturated or a mono- or polyunsaturated, unsubstituted or mono- or polysubstituted, aliphatic hydrocarbon residue;
wherein in each case “cycloaliphatic”, respectively independently, means a saturated or a mono- or polyunsaturated, unsubstituted or mono- or polysubstituted, mono- or multicyclic hydrocarbon residue, either alicyclic or wherein possibly one or two or more carbon atoms are replaced independently of one another by a heteroatom S, N or O;
wherein in each case with respect to “aliphatic” and “cycloaliphatic”, “mono- or polysubstituted”, respectively independently, means the mono- or polysubstitution of one or more hydrogen atoms by —F, -Cl, —Br, —I, —CN, —NO2, —CHO, ═O, —Rx, —C(═O)Rx, —C(═O)H, —C(═O)OH, —C(═O)ORx, —C(═O)NH2, —C(═O)NHRx, —C(═O)N(Rx)2, —OH, —ORx, —OC(═O)H, —OC(═O)Rx, —OC(═O)—ORx, —OC(═O)NHRx, —OC(═O)N(Rx)2, —SH, -SRx, —SO3H, —S(═O)1-2-Rx, —S(═O)1-2NH2, —S(═O)1-2NHRx, —NH2, —NHRx, —N(Rx)2, —N+(Rx)3, —N+(Rx)2 O−, —NHC(═O)Rx, —NHC(═O)ORx, —NHC(═O)NH2, —NHC(═O)NHRx, —NHC(═O)—N(Rx)2, —Si(Rx)3 or —PO(ORx)2;
wherein in each case “aryl”, respectively independently, means a carbocyclic ring system with at least one aromatic ring, but without heteroatoms in this ring, wherein, if necessary, the aryl residues can be condensed with further saturated, (partially) unsaturated or aromatic ring systems, and each aryl residue can be present in unsubstituted or mono- or polysubstituted form, wherein the aryl substituents can be the same or different and in any desired and possible position of the aryl;
wherein in each case “heteroaryl”, respectively independently, means a 5-, 6- or 7-membered cyclic aromatic residue, which contains 1, 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms, the same or different, are nitrogen, oxygen or sulphur, and the heterocycle can be unsubstituted or mono- or polysubstituted; wherein in the case of the substitution on the heterocycle the substituents can be the same or different and can be in any desired and possible position of the heteroaryl; and wherein the heterocycle can also be part of a bi- or polycyclic system;
wherein in each case with respect to “aryl” and “heteroaryl”, “mono- or polysubstituted”, respectively independently, means the mono- or polysubstitution of one or more hydrogen atoms of the ring system by substituents selected from the group comprising —F, —Cl, —Br, —I, —CN, —NO2, —CHO, ═O, —Rx, —C(═O)Rx, —C(═O)H, —C(═O)OH, —C(═O)ORx, —C(═O)NH2, —C(═O)NHRx, —C(═O)—N(Rx)2, —OH, —O(CH2)1-2O—, —ORx, —OC(═O)H, —OC(═O)Rx, —OC(═O)ORx, —OC(═O)NHRx, —OC(═O)N(Rx)2, —SH, -SRx, —SO3H, —S(═O)1-2-Rx , —S(═O)1-2NH2, —NH2, —NHRx, —N(Rx)2, —N+(Rx)3, —N+(Rx)2 O−, —NHC(═O)Rx, —NHC(═O)ORx, —NH—C(═O)NH2, —NHC(═O)NHRx, —NHC(═O)—N(Rx)2, —Si(Rx)3 and —PO(ORx)2; wherein if necessary N-ring atoms present can be respectively oxidized;
or a physiologically acceptable salt thereof or a physiologically acceptable solvate thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R7, R8 and R9, respectively independently, mean
—H, —F, —Cl, —Br, —I, —CN, —NO2, —CHO, —Rx, —OH, —ORx, —SH, -SRx, —SO3H, —S(═O)1-2-Rx, —S(═O)1-2NH2, —NH2, —NHRx or -N(Rx)2.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R7, R8 and R9, respectively independently, mean —H, —F, —Cl, —Br, —I, —Rx, —OH, —ORx, —NH2, —NHRx or -N(Rx)2.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R7, R8 and R9, respectively independently, mean —H, —F, —Cl, —Br, —I, —Rx, —OH, —ORx, —NH2, —NHRx or -N(Rx)2, wherein Rx, respectively independently, means —C1-8-aliphatic or —C3-12-cycloaliphatic;
wherein
—C1-8-aliphatic is preferably unsubstituted —(CH2)m—CH3, wherein m is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9; and/or
—C3-12-cycloaliphatic is preferably piperidinyl, piperazinyl or pyrrolidinyl, in each case unsubstituted.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R10 means —H, —F, —Cl, —Br, —I, —CN, —Rx, —OH, —ORx, —NH2, —NHRx or -N(Rx)2.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R10 means —H, —F, —Cl, —Br, —I, —CN, —Rx, —OH, —ORx, —NH2, —NHRx or -N(Rx)2, wherein Rx, respectively independently, means —C1-8-aliphatic or —C3-12-cycloaliphatic;
wherein
—C1-8-aliphatic is preferably —(CH2)m—CH3, wherein m is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9, in each case either unsubstituted or mono-, di- or trisubstituted with —F, or is preferably ethenyl, ethinyl, propenyl, propinyl, butenyl or butinyl, in each case unsubstituted; and/or
—C3-12-cycloaliphatic is preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted.

### Claim 7 (depends on 1)

The compound of claim 1, wherein
A2 means —CH or C-Rx, wherein Rx means —C1-8-aliphatic or —C3-12-cycloaliphatic; and A3 means C—R11;
A4 means C—R12; and A5 means C—R13; wherein R11, R12 and R13, respectively independently, mean —H, —F, —Cl, —Br, —I or —Rx, wherein Rx, respectively independently, means —C1-8-aliphatic or —C3-12-cycloaliphatic;
wherein
—C1-8-aliphatic is preferably unsubstituted —(CH2)m—CH3, wherein m is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9, or is preferably 1-methylethyl, iso-butyl or tert.-butyl, in each case unsubstituted; and/or
—C3-12-cycloaliphatic is preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R4, Rs and R6, respectively independently, mean —H, —Rx, —C(═O)Rx, —C(═O)H, —C(═O)OH, —C(═O)ORx,
—C(═O)NH2, —C(═O)NHRx, —C(═O)N(Rx)2, —OH, —ORx, —OC(═O)H, —OC(═O)Rx, —OC(═O)—ORx, —OC(═O)NHRx or —OC(═O)N(Rx)2, wherein Rx, respectively independently, means —C1-8-aliphatic or —C3-12-cycloaliphatic;
wherein
—C1-8-aliphatic is preferably —(CH2)m—CH3, wherein m is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9, in each case unsubstituted or mono- or disubstituted with —OH; and/or
—C3-12-cycloaliphatic is preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted; or
wherein R4 means —H or —(CH2)m—CH3, wherein m is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9, in each case unsubstituted or mono- or disubstituted with —OH.

### Claim 9 (depends on 1)

The compound of claim 1, wherein
B and C, respectively independently, mean —O—, N, —CH or C-Rx; wherein Rx, respectively independently, means C1-8-aliphatic which is preferably unsubstituted —(CH2)m—CH3, wherein m is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9; and/or
A1 means —O—, —S—, N or —CH.

### Claim 10 (depends on 1)

The compound of claim 1, wherein
R1, R2, R3, respectively independently, mean —H, —F, —Cl, —Br, —Rx, —C(═O)Rx, —C(═O)ORx, —C(═O)NHRx, —OH, ORx, —S(═O)1-2NH2, —S(═O)1-2NHRx, —CH2—S(═O)1-2NHRx, —NH2, —NHRx, -NH—S(═O)1-2-Rx, —NHC(═O)Rx, —N(S(═O)2—CH3)(C(═O)Rx) or —N(S(═O)2—CH3)2; or
R1 and R2 together form a ring which is unsubstituted —(CH2)~-, wherein n is 1, 2, 3, 4, 5, 6, 7, 8 or 9; or
R1 and R4 together form a ring which is unsubstituted —(CH2)~-, wherein n is 1, 2, 3, 4, 5, 6, 7, 8 or 9; or
unsubstituted —(CH2)o—NH—C(═O)—, wherein o is 1, 2, 3, 4, 5, 6, 7, 8 or 9; or unsubstituted —(CH2)p—C(CH3)(OH)—(CH2)q—O—, wherein p and q, respectively independently, are 1, 2, 3, 4, 5, 6, 7, 8 or 9.

### Claim 11 (depends on 1)

The compound of claim 1, wherein, unless defined otherwise,
with respect to “aliphatic” and “cycloaliphatic”, “mono- or polysubstituted”, respectively independently, means the mono- or polysubstitution of one or more hydrogen atoms by —F, —Cl, —Br, —I, —CN, —NO2, —CHO, ═O, —Rx, —OH, —ORx, —NH2, —NHRx or -N(Rx)2, wherein Rx, respectively independently, means —C1-8-aliphatic or —C3-12-cycloaliphatic; and/or
with respect to “aryl” and “heteroaryl”, “mono- or polysubstituted”, respectively independently, means the mono- or polysubstitution of one or more hydrogen atoms of the ring system by substituents selected from the group comprising —F, —Cl, —Br, —I, —CN, —NO2, —CHO, ═O or —OH; and/or
Rx, respectively independently, means
—C1-8-aliphatic, -C3-12-cycloaliphatic, -aryl or heteroaryl,
preferably C1-8-aliphatic or —C3-12-cycloaliphatic, preferably in each case unsubstituted.

### Claim 12 (depends on 1)

The compound of claim 1,
wherein with respect to general Formula (A) none of A1, B and C is —S—; and/or wherein with respect to general Formula (A) D is not —C—CN; and/or
which is not

### Claim 13 (depends on 1)

The compound of claim 1, wherein
H is Tritium (3H), and/or
F is 18F, and/or
C is 11C or 13C or 14C, and/or
O is 150, and/or
N is 13N, and/or
S is 35S, and/or
Cl is 36Cl, and/or
I is 125I or 131I.

### Claim 14 (depends on 1)

The compound of claim 1, which is selected from the group consisting of
1-(4-methoxyindolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (1);
1-(4-methoxyindolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)ethan-1-one (2);
2-((5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-fluorophenyl)amino)-1-(6-fluoro-5-methoxyindolin-1-yl)ethan-1-one (3);
2-((2-methoxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(4-methoxyindolin-1-yl)ethan-1-one (4);
2-((5-(2-ethyl-2H-tetrazol-5-yl)-2-methoxyphenyl)amino)-1-(4-methoxyindolin-1-yl)ethan-1-one (5);
1-(5-fluoro-1H-indol-1-yl)-2-((2-methoxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (6);
2-(5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenylamino)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone (7);
2-((3-fluoro-2-methoxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(4-methoxyindolin-1-yl)ethan-1-one (8);
1-(6-bromoindolin-1-yl)-2-((5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)amino)ethan-1-one (9);
1-(5-chloro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (10);
2-((5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)amino)-1-(5-methoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)ethan-1-one (11);
1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino) (12);
2-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)isothiazolidin-3-one 1,1-dioxide (13);
2-((5-(3-bromo-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)ethan-1-one (14);
2-((5-(3-ethynyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-methoxyindolin-1-yl)ethan-1-one (15);
1-(4-(3-hydroxypropoxy)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (16);
1-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)pyrrolidine-2,5-dione (17);
1-(4-(2-(2-hydroxyethoxy)ethoxy)indolin-1-yl)-2-((2-methyl-5-(3-vinyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (18);
2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-(2-(2-hydroxyethoxy)ethoxy)indolin-1-yl)ethan-1-one (19);
N-(1-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)glycyl)indolin-4-yl)methanesulfonamide (20);
2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-fluorophenyl)amino)-1-(4-(1-hydroxyethyl)indolin-1-yl)ethan-1-one (21);
1-(4-(2-hydroxypropan-2-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (22);
1-(4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (23);
1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)-2-((5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-(pyrrolidin-1-yl)phenyl)amino)ethan-1-one (24);
1-(4-(3-hydroxypyrrolidin-1-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)ethan-1-one (25);
1-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)glycyl)-N-methylindoline-4-sulfonamide (26);
1-(4-(2,6-dimethylmorpholino)indolin-1-yl)-2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)ethan-1-one (27);
1-(4-(hydroxymethyl)indolin-1-yl)-2-((2-methyl-5-(5-methylfuran-2-yl)phenyl)amino)ethan-1-one (28);
1-(4-(1-hydroxyethyl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (29);
1-(4-(3-hydroxy-3-methylbutoxy)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (30);
1-(4-(2-(2-hydroxyethoxy)ethoxy)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (31);
2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(4-(pyridin-3-yl)indolin-1-yl)ethan-1-one (32);
2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(4-(2,2,2-trifluoro-1-hydroxyethyl)indolin-1-yl)ethan-1-one (33);
2-((2-fluoro-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(4-methoxyindolin-1-yl)ethan-1-one (34);
1-(4-(1H-imidazol-1-yl)indolin-1-yl)-2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)ethan-1-one (35);
1-(4-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)indolin-1-yl)-2-((2-methyl-5-(5-methylfuran-2-yl)phenyl)amino)ethan-1-one (36);
1-(4-acetylindolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (37);
2-((5-(3-cyclopropyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)ethan-1-one (38);
2-((2-chloro-5-(3-chloro-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(4-hydroxyindolin-1-yl)ethan-1-one (39);
2-((5-(3-(difluoromethyl)-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-(2-hydroxypropan-2-yl)indolin-1-yl)ethan-1-one (40);
2-((2-fluoro-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)-1-(4-(2,2,2-trifluoro-1-hydroxyethyl)indolin-1-yl)ethan-1-one (41);
1-(5-methoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (42);
2-((2-fluoro-5-(5-methylfuran-2-yl)phenyl)amino)-1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)ethan-1-one (43);
1-(4-((2-hydroxy-2-methylpropyl)amino)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (44);
2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-(4-methylpiperazine-1-carbonyl)indolin-1-yl)ethan-1-one (45);
N-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)methanesulfonamide (46);
1-(4-(3-hydroxy-3-methylbutoxy)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)ethan-1-one (47);
1-(4-(1H-imidazol-1-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (48);
1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)ethan-1-one (49);
2-((5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2-methylphenyl)amino)-1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)ethan-1-one (50);
1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indoline-4-sulfonamide (51);
1-(indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (52);
2-((2-fluoro-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)-1-(4-(2-hydroxypropan-2-yl)indolin-1-yl)ethan-1-one (53);
1-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)imidazolidine-2,4-dione (54);
1-(4-(3-hydroxyoxetan-3-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (55);
2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-fluorophenyl)amino)-1-(4-(3-hydroxyazetidin-1-yl)indolin-1-yl)ethan-1-one (56);
methyl 1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indoline-3-carboxylate (57);
1-(3-(2-hydroxyethyl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (58);
N-methyl-1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indoline-3-carboxamide (59);
1-(4-(1,2-dihydroxypropan-2-yl)indolin-1-yl)-2-((2-fluoro-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)ethan-1-one (60);
2-((5-(3-(difluoromethyl)-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-(1,2-dihydroxypropan-2-yl)indolin-1-yl)ethan-1-one (61);
1-(4-(1,2-dihydroxypropan-2-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (62);
1-(4-(2-fluoro-1-hydroxypropan-2-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (63);
rel-(R)-1-(4-(1,2-dihydroxypropan-2-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (64);
rel-(R)-1-(4-(1,2-dihydroxypropan-2-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (65);
2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-(3-hydroxyazetidin-1-yl)indolin-1-yl)ethan-1-one (66);
2-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)propan-2-yl 2,3-dihydroxypropanoate (67);
1-(4-(3-hydroxypyrrolidin-1-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (68);
imino(methyl)((1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl) glycyl)indolin-4-yl)methyl)sulfanone (69);
1-(4-(1H-pyrazol-3-yl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (70);
2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-fluorophenyl)amino)-1-(4-(3-hydroxypyrrolidin-1-yl)indolin-1-yl)ethan-1-one (71);
2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-(piperazin-1-yl)indolin-1-yl)ethan-1-one (72);
1-(4-(1H-imidazol-4-yl)indolin-1-yl)-2-((2-methyl-5-(5-methylfuran-2-yl)phenyl)amino)ethan-1-one (73);
1-(4-aminoindolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (74);
1-(4-aminoindolin-1-yl)-2-((2-fluoro-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)ethan-1-one (75);
N-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)acetamide (76);
N-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)-N-(methylsulfonyl)acetamide (77);
N-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)-N-(methylsulfonyl)methanesulfonamide (78);
1-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)-1H-pyrrole-2,5-dione (79);
3-amino-1-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)pyrrolidine-2,5-dione (80);
(R)-N-(1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)pyrrolidine-2-carboxamide (81);
(2R,3R)-2,3-dihydroxy-4-((1-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)indolin-4-yl)amino)-4-oxobutanoic acid (82);
3-(1-((2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)glycyl)indolin-4-yl)imidazolidine-2,4-dione (83);
2-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)amino)-1-(4-hydroxyindolin-1-yl)ethan-1-one (84);
1-(4-hydroxyindolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (85);
1-(4-hydroxyindolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)ethan-1-one (86);
2-((1-((5-(3-ethyl-1,2,4-thiadiazol-5-yl)-2-methylphenyl)glycyl)indolin-4-yl)oxy)-2,2-difluoroacetic acid (87);
1-(4-(1-amino-2,2,2-trifluoroethyl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (88);
1-(4-(1-amino-2,2,2-trifluoroethyl)indolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)ethan-1-one (89);
1-(4-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (90);
1-(4-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-pyrrolo[2,3-c]pyridin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (91);
1-(4-(i-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (92);
1-(7-methoxy-1H-indol-3-yl)-2-((2-methoxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (93);
1-(5-fluoro-6-methoxy-1H-indol-3-yl)-2-((2-methoxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (94);
1-(6-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (95);
2-((5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)amino)-1-(6-methoxy-1H-indol-3-yl)ethan-1-one (96);
2-((5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)amino)-1-(5-fluoro-6-methoxy-1H-indol-3-yl)ethan-1-one (97);
2-((5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)amino)-1-(5-fluoro-6-methoxy-1-methyl-1H-indol-3-yl)ethan-1-one (98);
7-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)glycyl)-3,4-dihydro-[1,4]diazepino[6,7,1-hi]indol-1(2H)-one (99);
2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one (100);
2-((3-fluoro-2-methoxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(5-fluoro-6-methoxy-1H-indol-3-yl)ethan-1-one (101);
1-(1H-indol-3-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (102)
1-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (103);
2-((2-methoxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(1,6,7,8-tetrahydrocyclopenta[g]indol-3-yl)ethan-1-one (104);
1-(3-hydroxy-3-methyl-3,4-dihydro-2H-[1,4]oxazepino[2,3,4-hi]indol-7-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (105);
1-(1H-indol-3-yl)-2-((2-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)amino)ethan-1-one (106);
2-((2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)amino)-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one (107);
2-(4-bromo-5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenylamino)-1-(5-bromo-6-methoxy-1H-indol-3-yl)ethanone (108);
2-((4-bromo-5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)amino)-1-(6-methoxy-1H-indol-3-yl)ethan-1-one (109);
1-(7-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (110);
2-((5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2-methylphenyl)amino)-1-(1-methyl-1H-indol-3-yl)ethan-1-one (111);
1-(7-(1-hydroxyethyl)-1H-indol-3-yl)-2-((2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)ethan-1-one (112);
1-(4-(2-(2-hydroxyethoxy)ethoxy)indolin-1-yl)-2-((5-(5-isopropylpyridin-2-yl)-2-methylphenyl)amino)ethan-1-one (113);
2-((5-(5-cyclopropylpyridin-2-yl)-2-methylphenyl)amino)-1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)ethan-1-one (114);
2-((5-(5-chloropyridin-2-yl)-2-methylphenyl)amino)-1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)ethan-1-one (115);
1-(4-(hydroxymethyl)indolin-1-yl)-2-((2-methyl-5-(5-methylpyridin-2-yl)phenyl)amino)ethan-1-one (116);
1-(4-(2-hydroxy-2-methylpropoxy)indolin-1-yl)-2-((2-methyl-5-(5-methylpyridin-2-yl)phenyl)amino)ethan-1-one (117);
1-(5,6-difluoroindolin-1-yl)-2-((2-methoxy-5-(5-methylpyridin-2-yl)phenyl)amino)ethan-1-one (118);
methyl 1-((2-methoxy-5-(5-methylpyridin-2-yl)phenyl)glycyl)indoline-4-carboxylate (119);
2-((2-methoxy-5-(5-methylpyridin-2-yl)phenyl)amino)-1-(4-methoxyindolin-1-yl)ethan-1-one (120);
2-((5-(4,5-dimethylpyridin-2-yl)-2-methoxyphenyl)amino)-1-(4-hydroxyindolin-1-yl)ethan-1-one (121);
1-(5,6-difluoro-1H-indol-3-yl)-2-((3-(pyridin-2-yl)phenyl)amino)ethan-1-one (122);
2-((4-bromo-2-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl)amino)-1-(6-bromo-4-(1,2-dihydroxypropan-2-yl)indolin-1-yl)ethan-1-one (123);
and a physiologically acceptable salt thereof or a physiologically acceptable solvate thereof.

### Claim 15 (depends on 1)

A medicament comprising a compound according to claim 1.

### Claim 16 (depends on 1)

The compound of claim 1, for use as medicament.

### Claim 17 (depends on 1)

The compound according to claim 1 for use in the treatment of a disease or disorder selected from the group consisting of
pain, inflammation and cancer, preferably colon cancer; or
neuropathic pain, spinal cord injury, epilepsy, stroke, acute brain injury, multiple sclerosis, neurodegenerative diseases such as Parkinson's and Alzheimer's and amyotropic lateral sclerosis (ALS), obesity, obesity-dependent inflammation, artherosclerosis, allergen-induced airway inflammation, allergic asthma, airway remodeling, rheumatoid arthritis, colitis, alcohol-induced liver inflammation, steatohepatitis, inflammatory and fibrotic diseases, itch and cutaneous pain, muscle pain, chronic pain, diabetic neuropathy, trigeminal neuralgia, other types of pain, pain and depression comorbidity, liver fibrosis, hepatitits virus-induced hepatocellular carcinoma, prostate cancer, gastric cancer, breast cancer, glioma, colon cancer, and disorders of the central nervous system.

### Claim 18 (depends on 15)

The medicament according to claim 15 for use in the treatment of a disease or disorder selected from the group consisting of
pain, inflammation and cancer, preferably colon cancer; or
neuropathic pain, spinal cord injury, epilepsy, stroke, acute brain injury, multiple sclerosis, neurodegenerative diseases such as Parkinson's and Alzheimer's and amyotropic lateral sclerosis (ALS), obesity, obesity-dependent inflammation, artherosclerosis, allergen-induced airway inflammation, allergic asthma, airway remodeling, rheumatoid arthritis, colitis, alcohol-induced liver inflammation, steatohepatitis, inflammatory and fibrotic diseases, itch and cutaneous pain, muscle pain, chronic pain, diabetic neuropathy, trigeminal neuralgia, other types of pain, pain and depression comorbidity, liver fibrosis, hepatitits virus-induced hepatocellular carcinoma, prostate cancer, gastric cancer, breast cancer, glioma, colon cancer, and disorders of the central nervous system.
